peripheral blood of rheumatoid arthritis (RA) patients (pts), but differences between B-cell subsets distributions in early and late onset RA (LORA) are still unclear [1,2]. Objectives: To examine B-cell subsets in peripheral blood of healthy donors, early (disease duration <6 months) RA (ERA) and LORA pts by flow cytometry, and to analyze the association between B-cell subsets and RA activity. Methods: 24 active ERA pts (20F/4M); median age 54 years (range) (38-64); disease duration 5 months (4-6); DAS28 score 5.2 (4.7-5.9); RF+75%, ACCP+ 87.5% and 20 LORA pts (16F/4M); median age 58 years (range) (44-62); disease duration 12 years (4.5-17.5); DAS28 score 5.3 (4.6-6.2); both RF+ and ACCP+ 80%, were assessed for B-cell subpopulations and laboratory data: ESR, CRP. LORA pts were treated with DMARDs (anti-TNF-α, Methotrexate), glucocorticoids, and NSAIDS; ERA pts received NSAIDS only. CD19+B cells, memory B cells (CD19+CD27-), non-switched memory B cells (CD19+IgD+CD27+), switched memory B cells (CD19+IgD-CD27+), naïve (CD19+IgD+CD27-), double-negative (CD19+IgD-CD27-), transitional (CD19+IgD+CD10+CD38++CD27-) B cells, and plasmablasts (CD19+CD38+++IgD-CD27+CD20-) were analyzed using multicolor flow cytometry. Results: The median percentages (range) of non-switched memory B cells (CD19+IgD+CD27+) were lower in ERA and LORA RA cohorts compared to donors: 3.0% (1.6-5.5) and 6.2% (2.4-10.2) vs 7.4% (3.7-11.1), respectively, p<0.05 for both cases. In LORA pts, the median percentages (range) and absolute numbers of switched memory B cells (CD19+IgD+CD27-) were higher compared to both ERA pts and donors: 24,1% (14,0-42.3) vs 8,3% (4.4-12.9) and 12.8% (9.3-17.0); and 0.03 (0.02-0.05) vs 0.01 (0.006-0.02) and 0.02 (0.01-0.04), respectively; p<0.05 for all cases. The median percentages of naïve B cells (CD19+IgD+CD27-) were significantly higher in ERA pts compared to LORA pts and healthy donors: 75.3% (69.7-83.6) vs 54.3% (39.7-69.1) and 64.7% (57.6-72.4), respectively, p<0.05 for both cases. In ERA pts, we found a significant correlation between absolute numbers of non-switched memory B cells (CD19+IgD+CD27+), RF and anti-CCP: r=0.50 and 0.45, respectively, p<0.05 for both cases. In LORA pts, the percentage of memory B cells (CD19+CD27+) correlated positively with ESR (r=0.58), p<0.05; a positive association was observed between the absolute numbers of switched memory B cells (CD19+IgD-CD27+), CRP (r=0.48) 
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Results: A remarkable change in the distribution of Vγ9Vδ2 T cell functional subsets with an expansion of effector subsets and a reduction of naïve cells, was observed in the peripheral blood of RA patients, as compared to healthy donors, which were accompanied by modifications in proinflammatory cytokine expression. Particularly, T EM (effector memory) and T EMRA (effector memory terminally differentiated) cells resulted the major souce of IL-6 and IL-8. A significant correlation between miRNA expression and levels of IL-6 and IL-8 was found. The comparative analysis of miRNA expression among Vγ9Vδ2 T cell subsets, between RA patients and healthy controls showed a downregulation of miR106a-5p and miR20a-5p and an upregulation of miR 21a-5p among Vγ9Vδ2 Background: Insulin-like growth factor (IGF) 1 receptor is essential for cell energy metabolism. It plays a key role linking glucose and lipid metabolism of active cells and may turn pathogenic in uncontrolled tissue growth in tumours. In rheumatoid arthritis (RA), the IGF-1R signalling is activated supporting expansion of the inflamed synovia. Objectives: The aim of the present study was to understand the place of IGF-1R expression and signalling for development of adaptive immune responses in the setting of prospective RA cohort and in experimental arthritis. Methods: Clinical associations of IGF1R expression in leukocytes of the peripheral blood were studied in 84 female RA patients with mean disease duration 8 years, all treated with methotrexate. Consequences of the IGF1R signalling inhibition for arthritis were studied in mBSA immunised Balb/c mice treated with NT157 compound promoting degradation of the insulin receptor substrates IRS-1/2. Results: In RA patients, high expression of IGF1R in leukocytes was associated with systemic inflammation as verified by higher transcription factor NF-kB (p=0.033), serum levels of IL-6 (p=0.006) and erythrocyte sedimentation rate (p=0.003), and higher pain perception (VAS, p=0.019). Additionally, women with high IGF1R were often in need of combined DMARD treatment (p=0.045). Phosphorylated IGF1R and STAT3 enrich T cells infiltrate in RA synovia. Treatment with NT157 rendered no metabolic consequences to mouse body weight and serum glucose levels. NT157 inhibited the phosphorylation of IGF1R and STAT3 in synovia, and alleviated arthritis and erosions in mice. It also reduced IGF1R+ T cell population in spleen and despaired ERK and Akt signalling. This limited the ability of mBSA-specific T cells to produce IL-6 (p=0.013), IFNg (p=0.024) and IL-17 (p=0.0097). The reduction of IL-6 and IL-17 levels was associated with changed RoRgt/FoxP3 balance. Background: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune diseases, generating impetus to develop alternate strategies that provide activity with rapid onset and no B-cell depletion. To this end, MGD010, a bispecifc DART ® molecule, was designed to exploit the inhibitory function of the checkpoint molecule, CD32B, (FcγRIIb) via its simultaneous co-ligation with the BCR component, CD79B. Initial phase 1 studies performed in healthy subjects demonstrated MGD010 was well tolerated in a single-dose, dose escalation to up to 10 mg/kg, with no evidence of peripheral B-cell activation or depletion. MGD010 exhibited pharmacokinetic properties of an antibody-based molecule, with dose-dependent B-cell occupancy saturating at >1mg/kg and diminished propensity for ex-vivo BCR-induced B-cell activation (1). To further understand the potential for MGD010 to modulate ongoing immune responses, the impact of MGD010 on the immune response to Hepatitis A (HAV) vaccination, a T-cell dependent neo-antigen challenge, was evaluated in normal healthy subjects. Objectives: To determine effects of MGD010 on humoral and cellular immune responses in normal healthy volunteers.
Methods:
This was an open label, placebo controlled cohort-expansion in normal healthy volunteers. Subjects (n=8 per group) were randomly assigned to receive an IV administration of a single dose of 3 or 10 mg/kg MGD010 or placebo. All subjects received a single intramuscular dose of hepatitis A vaccine (HAV) (1.0 mL or ∼50U) 24 hours after administration of MGD010 or placebo. Subjects were monitored for adverse events for 56 days after administration of drug or placebo. Analyses included peripheral lymphocyte
